Behavior and Social Issues

, Volume 15, Issue 2, pp 152–177 | Cite as

Behavior Analysis of Psychotic Disorders: Scientific Dead End or Casualty of the Mental Health Political Economy?

  • Stephen E. WongEmail author
Lead Article


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abbott, A. (1988). The system of professions: An essay on the division of expert labor. Chicago: The University of Chicago Press.CrossRefGoogle Scholar
  2. Abraham, J. (1995). Science, politics, and the pharmaceutical industry: Controversy and bias in drug regulation. London: University College London (UCL) Press.Google Scholar
  3. Allen, D. J., & Magaro, P. A. (1971). Measures of change in token-economy programs. Behaviour Research and Therapy, 9, 311–318. Scholar
  4. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.Google Scholar
  5. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.-rev.). Washington, DC: Author.Google Scholar
  6. American Psychiatric Association. (2003, September 25). American Psychiatric Association statement on diagnosis and treatment of mental disorders (Release No. 03–39). Washington, DC: Author.Google Scholar
  7. Anderson, L. T., & Alpert, M. (1974). Operant analysis of hallucination frequency in a hospitalized schizophrenic. Journal of Behavior Therapy and Experimental Psychiatry, 5, 13–18. Scholar
  8. Andreasen, N., & Flaum, M. (1994). Characteristic symptoms of schizophrenia. In T. A. Widiger, A. J. Frances, H. A. Pincus, M. B. First, R. Ross, & W. Davis (Eds.), DSM-IV sourcebook: Volume 1 (pp. 351–379). Washington, DC: American Psychiatric Association.Google Scholar
  9. Andreasen, N., Flaum, M., & Arndt, S. (1992). The comprehensive assessment of symptoms and history (CASH): An instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry, 29, 615–623. Scholar
  10. Angell, M. (2004). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.Google Scholar
  11. Antonuccio, D. O., Danton, W. G., & McClanahan, T. M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist, 58, 1028–1043. Scholar
  12. Attowe, J. M., & Krasner, L. (1968). Preliminary report on the application of contingent reinforcement procedures (token economy) on a “chronic” psychiatric ward. Journal of Abnormal Psychology, 73, 37–43. Scholar
  13. Ayllon, T., & Azrin, N. H. (1965). The measurement and reinforcement of behavior of psychotics. Journal of the Experimental Analysis of Behavior, 8, 357–383. Scholar
  14. Ayllon, T., & Azrin, N. (1968). The token economy: A motivational system for therapy and rehabilitation. Englewood Cliffs, NJ: Prentice-Hall, Inc.Google Scholar
  15. Ayllon, T., & Haughton, E. (1964). Modification of symptomatic verbal behaviour of mental patients. Behaviour Research and Therapy, 2, 87–97. Scholar
  16. Ayllon, T., & Michael, J. (1959). The psychiatric nurse as a behavioral engineer. Journal of the Experimental Analysis of Behavior, 2, 323–334. Scholar
  17. Barton, R. (1999). Psychosocial rehabilitation services in community support systems: A review of outcomes and policy recommendation. Psychiatric Services, 50, 525–534.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Bellack, A. S. (1986). Schizophrenia: Behavior therapy’s forgotten child. Behavior Therapy, 17, 199–214. Scholar
  19. Bero, L. A., & Rennie, D. (1996). Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care, 12(2), 209–237. Scholar
  20. Blashfield, R. K., & Fuller, A. K. (1996). Predicting the DSM-V. Journal of Nervous and Mental Disease, 184(1), 4–7. Scholar
  21. Bodenheimer, T. (2000). Uneasy alliance: Clinical investigators and the pharmaceutical industry. The New England Journal of Medicine, 342(20), 1539–1544. Scholar
  22. Boudewyns, P. A., Fry, T. J., & Nightingale, E. J. (1986). Token economy programs in VA Medical Centers: Where are they today? the Behavior Therapist, 6, 126–127.Google Scholar
  23. Boyle, M. (1990). Schizophrenia: A scientific delusion? New York: Routledge.Google Scholar
  24. Braslow, J. (1997). Mental ills and bodily cures: Psychiatric treatment in the first half of the twentieth century. Berkeley, CA: University of California Press.Google Scholar
  25. Breggin, P. R. (1991). Toxic psychiatry. New York: St. Martin’s Press.Google Scholar
  26. Breggin, P. R. (1997). Brain disabling treatments in psychiatry: Drugs, electroshock, and the role of the FDA. New York: Springer.Google Scholar
  27. Brown, P., & Funk, S. C. (1986). Tardive dyskinesia: Barriers to the professional recognition of an iatrogenic disease. Journal of Health and Social Behavior, 27, 116–132. Scholar
  28. Carlson, C. G., Hersen, M., & Eisler, R. M. (1972). Token economy programs in the treatment of hospitalized adult psychiatric patients. The Journal of Nervous and Mental Disease, 155(3), 192–204. Scholar
  29. Cauchon, D. (2000, September 25). FDA advisors tied to industry. USA Today, pp. 1A, 10A.Google Scholar
  30. Cohen, C. I. (1993). The biomedicalization of psychiatry: A critical overview. Community Health Journal, 29, 509–521.Google Scholar
  31. Cohen, D. (1988). Social work and the psychotropic drug treatments. Social Service Review, 62, 576–599. Scholar
  32. Cohen, D. (Ed.) (1990). Challenging the therapeutic state: Critical perspectives on psychiatry and The mental health system. The Journal of Mind and Behavior, 11(3/4), 247–574.Google Scholar
  33. Cohen, D. (Ed.) (1994a). Challenging the therapeutic state, Part two: Further disquisitions on the mental health system. The Journal of Mind and Behavior, 15(3/4), 1–198.Google Scholar
  34. Cohen, D. (1994b). Neuroleptic drug treatment of schizophrenia: The state of confusion. The Journal of Mind and Behavior, 15(1/2), 139–156.Google Scholar
  35. Cohen, D. (1997). A critique of the use of neuroleptic drugs in psychiatry. In S. Fisher & R. P. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 173– 228). New York: John Wiley & Sons, Inc.Google Scholar
  36. Cohen, D. (2002). Research on the drug treatment of schizophrenia: A critical appraisal and implications for social work education. Journal of Social Work Education, 38, 217–239.CrossRefGoogle Scholar
  37. Cohen, D., & McCubbin, M. (1990). The political economy of tardive dyskinesia: Asymmetries in power and responsibility. The Journal of Mind and Behavior, 11(3/4), 219–242.Google Scholar
  38. Cohen, D., McCubbin, M., Collin, J., & Perodeau, G. (2001). Medications as social phenomena. Health, 5(4), 441–469. Scholar
  39. Cohen, J. S. (2001). Overdose: The case against the drug companies. New York: Jeremy P. Tarcher/Putnam.Google Scholar
  40. Conrad, P. (2001). Genetic optimism: Framing genes and mental illness in the news. Culture, Medicine and Psychiatry, 25, 225–247. Scholar
  41. Miracle drugs or media drugs? (1992, March). Consumer Reports, pp. 142–146.Google Scholar
  42. Cooksey, E. C. & Brown, P. (1998). Spinning on its axes: DSM and the social construction of psychiatric diagnoses. International Journal of Health Services, 28(3), 525–554. Scholar
  43. Corrigan, P. W., Kwartarini, W. Y., & Pramana, W. (1992). Staff perceptions of barriers to behavior therapy at a psychiatric hospital. Behavior Modification, 16(1), 132–144. Scholar
  44. Corrigan, P. W., Liberman, R. P., & Wong, S. E. (1993). Recreational therapy and behavior management on inpatient units: Is recreational therapy therapeutic? Journal of Nervous and Mental Disease, 181, 644–646. Scholar
  45. Corrigan, P. W., Williams, O. B., McCracken, S. G., Kommana, S., Edwards, M., & Brunner, J. (1998). Staff attitudes that impede the implementation of behavioral treatment programs. Behavior Modification, 22, 548–562. Scholar
  46. de Girolamo, G. (1996). WHO studies on schizophrenia: An overview of the results and their implications for the understanding of the disorder. In P. R. Breggin & E. M. Stern (Eds.), Psychosocial approaches to deeply disturbed persons. New York: Haworth Press.Google Scholar
  47. De Grandpre, R. (1999). Ritalin nation: Rapid-fire culture and the transformation of human consciousness. New York: W. W. Norton & Company.Google Scholar
  48. Dickersin, K., Chan, S., Chalmers, T. C., Sacks, H. S., & Smith, H. (1987). Publication bias and clinical trials. Controlled Clinical Trials, 8(4), 343–353. Scholar
  49. Eli Lilly and Company Annual Report, Notice of Annual Meeting, and Proxy Statement. (2003). Retrieved April 17, 2004, from
  50. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Journal of Medicine (BMJ), 321, 1371–1376. 10.1136/bmj.321.7273.1371CrossRefGoogle Scholar
  51. Gelman, S. (1999). Medicating schizophrenia: A history. New Jersey: Rutgers University Press.Google Scholar
  52. Glynn, S. M. (1990). Token economy approaches for psychiatric patients: Progress and pitfalls over 25 years. Behavior Modification, 14, 383–407. 10.1177/01454455900144002CrossRefPubMedPubMedCentralGoogle Scholar
  53. Glynn, S. M., & Mueser, K. T. (1986). Social learning for chronic mental patients. Schizophrenia Bulletin, 12(4), 648–668. 10.1093/schbul/12.4.648CrossRefPubMedPubMedCentralGoogle Scholar
  54. Goode, E. (2003, December 16). British ignite debate in U.S. on drugs and suicide. The New York Times. Retrieved December 16, 2003 from database.Google Scholar
  55. Gosden, R., & Beder, S. (2001). Pharmaceutical industry agenda setting in mental health policies. Ethical Human Sciences and Services, 3(3), 147–159.PubMedPubMedCentralGoogle Scholar
  56. Hall, J., & Baker, R. (1973). Token economy systems: Breakdown and control. Behaviour Research and Therapy, 11, 253–263. 10.1016/0005-7967(73)90001-6CrossRefPubMedPubMedCentralGoogle Scholar
  57. Hall, J. N., Baker, R. D., & Hutchison, K. (1977). A controlled evaluation of token economy procedures with chronic schizophrenic patients. Behaviour Research and Therapy, 15, 261–283. 10.1016/0005-7967(77)90023-7CrossRefPubMedPubMedCentralGoogle Scholar
  58. Harris, G. (2004, September 14). F.D.A. links drugs to being suicidal. The New York Times. Retrieved September 15, 2004 from the database.Google Scholar
  59. Henderson, J. D., & Scoles, P. E. (1970). Conditioning techniques in a community-based operant environment for psychotic men. Behavior Therapy, 1, 245–251. 10.1016/S0005-7894(70)80037-5CrossRefGoogle Scholar
  60. Hersen, M., & Bellack, A. S. (1976). A multiple-baseline analysis of social-skills training in chronic schizophrenics. Journal of Applied Behavior Analysis, 9, 239–245. 10.1901/jaba.1976.9-239CrossRefPubMedPubMedCentralGoogle Scholar
  61. Hersen, M., Eisler, R. M., Smith, B. S., & Agras, W. S. (1972). A token reinforcement ward for young psychiatric patients. American Journal of Psychiatry, 129(2), 142–233.CrossRefGoogle Scholar
  62. Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992). Schizophrenia: Manifestations, incidence, and course in different cultures: A World Health Organization ten-country study. Psychological Medicine, Monograph Supplement 20, 1–97. 10.1017/S0264180100000904CrossRefGoogle Scholar
  63. Johnson, A. B. (1990). Out of bedlam: The truth about deinstitutionalization. New York: Basic Books.Google Scholar
  64. Johnston, J. M., & Shook, G. (1987). Developing behavior analysis at the state level. The Behavior Analyst, 10, 199–233.CrossRefPubMedPubMedCentralGoogle Scholar
  65. Kale, R. J., Kaye, J. H., Whelan, P. A., & Hopkins, B. L. (1968). The effects of reinforcement on the modification, maintenance, and generalization of social responses of mental patients. Journal of Applied Behavior Analysis, 1, 307–314. 10.1901/jaba.1968.1-307CrossRefPubMedPubMedCentralGoogle Scholar
  66. Kazdin, A. E. (1974). A review of token economy treatment modalities. In D. Harshbarger & R. F. Maley (Eds.), Behavior analysis and system analysis: An integrative approach to mental health programs. Kalamazoo, MI: Behaviordelia, Inc.Google Scholar
  67. Kazdin, A. E. (1977). The token economy (pp. 85–93). New York: Plenum Press.CrossRefGoogle Scholar
  68. Kazdin, A. E. (1983). Failure of persons to respond to the token economy. In E. B. Foa & P. Emmelkamp (Eds.), Failures in behavior therapy (pp. 335–354). New York: Wiley.Google Scholar
  69. Kirk, S. A., & Kutchins, H. (1992). The selling of the DSM: The rhetoric of science in psychiatry. New York: Aldine De Gruyter.Google Scholar
  70. Kirk, S. A., & Kutchins, H. (1994). The myth of the reliability of the DSM. The Journal of Mind and Behavior, 15 (1/2),71–86.Google Scholar
  71. Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002). The emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment, 5, Article 23, Retrieved December 9, 2003 from Scholar
  72. Krimsky, S. (2003). Science in the private interest: Has the lure of profits corrupted biomedical research? Lanham, MD: Rowman & Littlefield Publishers, Inc.Google Scholar
  73. Kutchins, H., & Kirk, S. A. (1997). Making us crazy -- DSM: The psychiatric bible and the creation of mental disorders. New York: Free Press.Google Scholar
  74. Layng, T. V., & Andronis, P. T. (1984). Toward a functional analysis of delusional speech and hallucinatory behavior. The Behavior Analyst, 7(2), 139–156.CrossRefPubMedPubMedCentralGoogle Scholar
  75. Lauriello, J., Bustillo, J., & Keith, S. J. (1999). A critical review of research on psychosocial treatment of schizophrenia. Biological Psychiatry, 46(10), 1409–1417. 10.1016/S0006-3223(99)00100-6CrossRefPubMedPubMedCentralGoogle Scholar
  76. Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003). New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet, 361, 1581–1589. 10.1016/S0140-6736(03)13306-5CrossRefPubMedPubMedCentralGoogle Scholar
  77. Liberman, R. P. (1980). A review of Paul and Lentz’s psychological treatment for chronic mental patients: Milieu versus social-learning programs. Journal of Applied Behavior Analysis, 13, 367–371. 10.1901/jaba.1980.13-367CrossRefPubMedPubMedCentralGoogle Scholar
  78. Liberman, R. P., King, L. W., & De Risi, W. J. (1976). Behavior analysis and therapy in community mental health. In H. Leitenberg (Ed.), Handbook of behavior modification and behavior therapy (pp. 566–603). Englewood Cliffs, NJ: Prentice Hall.Google Scholar
  79. Liberman, R. P., Teigen, J., Patterson, R., & Baker, V. (1973). Reducing delusional speech in chronic paranoid schizophrenics. Journal of Applied Behavior Analysis, 6, 57–64. 10.1901/jaba.1973.6-57CrossRefPubMedPubMedCentralGoogle Scholar
  80. Liberman, R. P., Wallace, C., Teigen, J., & Davis, J. (1974). Interventions with psychotic behavior. In K. S. Calhoun, H. E. Adams, & K. M. Mitchell (Eds.), Innovative treatment methods in psychopathology (pp. 323–412.). New York: John Wiley & Sons.Google Scholar
  81. Lindsley, O. R. (1960). Characteristics of the behavior of chronic psychotics as revealed by freeoperant conditioning methods. Diseases of the Nervous System (Monograph Supplement), 21, 66–78.Google Scholar
  82. Lindsley, O. R., & Skinner, B. F. (1954). A method for the experimental analysis of the behavior of psychotic patients. American Psychologist, 9, 419–420.Google Scholar
  83. Little, S. (2001, September/October). The other drug war – Companies spent $177 million on lobbying in 1999–2000. Public Citizen News, 21(5), 5.Google Scholar
  84. Lloyd, K. E., & Garlington, W. K. (1968). Weekly variations in performance on a token economy ward. Behaviour Research and Therapy, 6, 407–410. 10.1016/0005-7967(68)90020-XCrossRefPubMedPubMedCentralGoogle Scholar
  85. Mace, F. C., Webb, M. E., Sharkey, R. W., Mattson, D. M., & Rosen, H. S. (1988). Functional analysis and treatment of bizarre speech. Journal of Behavior Therapy and Experimental Psychiatry, 19(4), 289–296. 10.1016/0005-7916(88)90060-2CrossRefPubMedPubMedCentralGoogle Scholar
  86. Mace, F. C., & Lalli, J. S. (1991). Linking descriptive and experimental analyses in the treatment of bizarre speech. Journal of Applied Behavior Analysis, 24, 553–562. 10.1901/jaba.1991.24-553CrossRefPubMedPubMedCentralGoogle Scholar
  87. Massel, H. K., Corrigan, P. W., Liberman, R. P., & Milan, M. A. (1991). Conversational skills training of thought-disordered schizophrenic patients through attention focusing. Psychiatry Research, 38, 51–61. 10.1016/0165-1781(91)90052-QCrossRefPubMedPubMedCentralGoogle Scholar
  88. Miracle drugs or media drugs? (1992, March). Consumer Reports, 142–146.Google Scholar
  89. Mosher, L., & Burti, L. (1994). Community mental health: A practical guide (pp. 28–31). New York: W. W. Norton & Company.Google Scholar
  90. Mosk, M. D., Kuehnel, T. G., Friedman, D. S., Collier, R., & Turley, F. (1988). Behavior therapy in a state hospital: Overcoming obstacles to implementation. the Behavior Therapist, 11, 119–122.Google Scholar
  91. Moss, G. R. (1983). Behavioral technology and hospital psychiatry: Considerations from the private sector. Analysis and Interventions in Developmental Disabilities, 3, 205–214. 10.1016/0270-4684(83)90015-0CrossRefGoogle Scholar
  92. Moss, G. R. (1993). A commentary on the status of the behavioral approach in the healthcare marketplace. Journal of Behavior Therapy & Experimental Psychiatry, 24 (4), 311–319. 10.1016/0005-7916(93)90055-2CrossRefGoogle Scholar
  93. Moss, G. R., & Liberman, R. P. (1975). Empiricism in psychotherapy: Behavioral specification and measurement. The British Journal of Psychiatry, 126, 73–80. 10.1192/bjp.126.1.73CrossRefPubMedPubMedCentralGoogle Scholar
  94. Mueser, K. T., Torrey, W. C., Lynde, D., Singer, P., & Drake, R. E. (2003). Implementing evidence-based practices for people with severe mental illness. Behavior Modification, 27(3), 387–411. 10.1177/0145445503027003007CrossRefPubMedPubMedCentralGoogle Scholar
  95. National Institute of Mental Health. (2001) NIMH research grants to colleges and universities by academic department fiscal years 1976–2000. (Graph) Retrieved August 31, 2001, from
  96. National Institute of Mental Health. (2002). Schizophrenia. Retrieved July 3, 2003, from
  97. Nelson, G. L., & Cone, J. D. (1979). Multiple-baseline analysis of a token economy for psychiatric inpatients. Journal of Applied Behavior Analysis, 12, 255–271. 10.1901/jaba.1979.12-255CrossRefPubMedPubMedCentralGoogle Scholar
  98. O’Brien, F., & Azrin, N. H. (1972). Symptom reduction by functional displacement in a token economy: A case study. Journal of Behavior Therapy & Experimental Psychiatry, 3, 205–207. 10.1016/0005-7916(72)90075-4CrossRefGoogle Scholar
  99. Pam, A. (1990). A critique of the scientific status of biological psychiatry. Acta Psychiatrica Scandinavica, 82 (Supplement 362), 1–35. 10.1111/j.1600-0447.1990.tb06868.xCrossRefGoogle Scholar
  100. Patterson, R. L., & Teigen, J. R. (1973). Conditioning and post-hospital generalization of nondelusional responses in a chronic psychotic patient. Journal of Applied Behavior Analysis, 6, 65–70 10.1901/jaba.1973.6-65CrossRefPubMedPubMedCentralGoogle Scholar
  101. Paul, G. L., & Lentz, R. J. (1977). Psychosocial treatment of chronic mental patients: Milieu versus social-learning programs. Cambridge, MA: Harvard University Press.Google Scholar
  102. Paul, G. L., & Menditto, A. A. (1992). Effectiveness of inpatient treatment programs for mentally ill adults in public psychiatric facilities. Applied and Preventive Psychology, 1, 41–63. 10.1016/S0962-1849(05)80133-7CrossRefGoogle Scholar
  103. Penn, D. L., & Mueser, K. T. (1996). Research update on the psychosocial treatment of schizophrenia. American Journal of Psychiatry, 153(3), 607–617.PubMedPubMedCentralGoogle Scholar
  104. Peterson, M. (2004, February 1). Making drugs, shaping the rules. The New York Times. Retrieved February 1, 2004 from the database.Google Scholar
  105. Pinkston, E. M., & Herbert-Jackson, E. W. (1975). Modification of irrelevant and bizarre verbal behavior using parents as therapists. Social Service Review, 49, 46–63. 10.1086/643209CrossRefGoogle Scholar
  106. Public Citizen Health Research Group. (2001, April). High drug prices for research or profit? Health Letter, 17(4), 8. Washington, DC: Author.Google Scholar
  107. Ross, C. A., & Pam, A. (1995). Pseudoscience in biological psychiatry: Blaming the body. New York: John Wiley & Sons.Google Scholar
  108. Rutherford, A. (2003). Skinner boxes for psychotics: Operant conditioning at Metropolitan State Hospital. The Behavior Analyst, 26, 267–279.CrossRefPubMedPubMedCentralGoogle Scholar
  109. Safer, D. J. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. The Journal of Nervous and Mental Disease, 190(9), 583–592. 10.1097/00005053-200209000-00002CrossRefGoogle Scholar
  110. Salzinger, K. (1973). Schizophrenia: Behavioral aspects. New York: John Wiley & Sons.Google Scholar
  111. Salzinger, K., & Pisoni, S. (1958). Reinforcement of affect responses of schizophrenics during the clinical interview. Journal of Abnormal and Social Psychology, 57(1), 84–90. 10.1037/h0040304CrossRefGoogle Scholar
  112. Salzinger, K., & Pisoni, S. (1960). Reinforcement of verbal affect responses of normal subjects during the interview. Journal of Abnormal and Social Psychology, 60(1), 127–130. 10.1037/h0044056CrossRefPubMedPubMedCentralGoogle Scholar
  113. Salzinger, K., & Pisoni, S. (1961). Some parameters of verbal affect responses in schizophrenic subjects. Journal of Abnormal and Social Psychology, 63(3), 511–516. 10.1037/h0042648CrossRefPubMedPubMedCentralGoogle Scholar
  114. Salzinger, K., Portnoy, S., & Feldman, R. S. (1966). Verbal behavior in schizophrenics and some comments toward a theory of schizophrenia. In P. H. Hoch, & Zubin, J. (Eds.), Psychopathology of schizophrenia (pp. 98–128). New York: Grune & Stratton.Google Scholar
  115. Salzinger, K., Portnoy, S., Pisoni, D. B., & Feldman, R. S. (1970). The immediacy hypothesis and response-produced stimuli in schizophrenic speech. Journal of Abnormal Psychology, 76(2), 258–264. 10.1037/h0029887CrossRefPubMedPubMedCentralGoogle Scholar
  116. Schock, K., Clay, C., & Cipani, E. (1998). Making sense of schizophrenic symptoms; delusional statements and behavior may be functional in purpose. Journal of Behavior Therapy and Experimental Psychiatry, 29(2), 131–141. 10.1016/S0005-7916(98)00010-XCrossRefPubMedPubMedCentralGoogle Scholar
  117. Scott, J. E. & Dixon, L. B. (1995). Psychological interventions for schizophrenia. Schizophrenia Bulletin, 21(4), 621–630. 10.1093/schbul/21.4.621CrossRefPubMedPubMedCentralGoogle Scholar
  118. Scotti, J. R., McMorrow, M. J., & Trawitzki, A. L. (1993). Behavioral treatment of chronic psychiatric disorders: Publication trends and future directions. Behavior Therapy, 24, 527–550. 10.1016/S0005-7894(05)80316-8CrossRefGoogle Scholar
  119. Siebert, A. (1999). Brain disease hypothesis for schizophrenia disconfirmed by all evidence. Ethical Human Sciences and Services, 1(2), 179–189.Google Scholar
  120. Siegel, M. (2001, July 16). Needed: Rx for Drug Costs. The Nation, 273(3), 6–7.Google Scholar
  121. Schafer, H. H., & Martin, P. L. (1966). Behavioral therapy for “apathy” of hospitalized schizophrenics. Psychological Reports, 19, 1147–1158. 10.2466/pr0.1966.19.3f.1147CrossRefGoogle Scholar
  122. Silverstein, K. (1999, November/December). An influential mental health nonprofit finds its ‘grassroots’ watered by pharmaceutical millions. Retrieved April 4, 2004, from Scholar
  123. Skinner, B. F., Solomon, H. C., & Lindsley, O. R. (1954). A new method for the experimental analysis of the behavior of psychotic patients. Journal of Nervous and Mental Disease, 120, 403–406.CrossRefGoogle Scholar
  124. Stahl, J. R., & Leitenberg, H. (1976). Behavioral treatment of the chronic mental hospital patient. In H. Leitenberg (Ed.), Handbook of behavior modification and therapy (pp. 211–241). Englewood Cliffs, NJ: Prentice-Hall.Google Scholar
  125. Swazey, J. P. (1974). Chlorpromazine in psychiatry: A study in innovation. Cambridge, MA: The MIT Press.Google Scholar
  126. Turner, S. M., & Luber, R. F. (1980). The token economy in day hospital settings: Contingency management or information feedback. Journal of Behavior Therapy and Experimental Psychiatry, 11, 89–94. 10.1016/0005-7916(80)90002-6CrossRefGoogle Scholar
  127. U.S. Department of Health and Human Services. (1999). Chapter 2, Overview of etiology. In Mental health: A report of the Surgeon General. Retrieved January 26, 2004, from
  128. U.S. Food and Drug Administration. (2004). FDA’s Mission Statement. Retrieved March 23, 2004, from
  129. Valenstein, E. S. (1999). Blaming the brain: The truth about drugs and mental health. New York: The Free Press.Google Scholar
  130. Vergano, D. (2001, May 17). Filed under F (for forgotten): Drug companies send unfavorable research to the nether regions. USA Today, D8.Google Scholar
  131. Whitaker, R. (1998, November 17). Lure of riches fuels testing. The Boston Globe. Retrieved August 23, 2003 from the database.Google Scholar
  132. Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. Cambridge, MA: Perseus Books.Google Scholar
  133. Wilder, D. A., Masuda, A., O’Connor, C., & Baham, M. (2001). Brief functional analysis and treatment of bizarre vocalizations in an adult with schizophrenia. Journal of Applied Behavior Analysis, 34, 65–68. 10.1901/jaba.2001.34-65CrossRefPubMedPubMedCentralGoogle Scholar
  134. Wilder, D. A., White, H., Yu, M. (2003). Functional analysis and intervention for bizarre speech exhibited by an adult with schizophrenia: A replication and extension. Behavioral Interventions, 18, 43–52. 10.1002/bin.128CrossRefGoogle Scholar
  135. Williams, J. B. W., Gibbon, M., First, M. B., Spitzer, R. L., Davies, M., Borus, J., Howes, M. J., Kane, J., Pope, H. G., Rounsaville, B., & Wittchen, H. (1992). The structured clinical interview for the DSM-III-R (SCID): II. Multisite Test-Retest Reliability. Archives of General Psychiatry, 49, 630–636. 10.1001/archpsyc.1992.01820080038006CrossRefPubMedPubMedCentralGoogle Scholar
  136. Winkler, R. C. (1970). Management of chronic psychiatric patients by a token reinforcement system. Journal of Applied Behavior Analysis, 3, 47–55. 10.1901/jaba.1970.3-47CrossRefPubMedPubMedCentralGoogle Scholar
  137. Wincze, J. P., Leitenberg, H., & Agras, W. S. (1972). The effects of token reinforcement and feedback on the delusional verbal behavior of chronic paranoid schizophrenics. Journal of Applied Behavior Analysis, 5, 247–262. 10.1901/jaba.1972.5-247CrossRefPubMedPubMedCentralGoogle Scholar
  138. Wolfe, S. M. (2002). Direct-to-consumer advertising – Education or emotion promotion? New England Journal of Medicine, 346(7), 524–526. 10.1056/NEJM200202143460713CrossRefPubMedPubMedCentralGoogle Scholar
  139. Wong, S. E. (1996). Psychosis. In M. Mattaini & B. A. Thyer (Eds.), Finding solutions to social problems: Behavioral strategies for change (pp. 319–343). Washington, D.C.: American Psychological Association.CrossRefGoogle Scholar
  140. Wong, S. E., Flanagan, S. G, Kuehnel, T. G., Liberman, R. P., Hunnicutt, R., & Adams-Badgett, J. (1988). Training chronic mental patients to independently practice personal grooming skills. Hospital and Community Psychiatry, 39, 874–879.PubMedPubMedCentralGoogle Scholar
  141. Wong, S. E., Terranova, M. D., Bowen, L., Zarate, R., Massel, H. K., & Liberman, R. P. (1987). Providing independent recreational activities to reduce sterotypic vocalizations in chronic schizophrenics. Journal of Applied Behavior Analysis, 20, 77–81. 10.1901/jaba.1987.20-77CrossRefPubMedPubMedCentralGoogle Scholar
  142. Wong, S. E., Martinez-Diaz, J. A., Massel, H. K., Edelstein, B. A., Wiegand, W., Bowen, L., & Liberman, R. P. (1993). Conversational skills training with schizophrenic inpatients: A study of generalization across settings and conversants. Behavior Therapy, 24, 285–304. 10.1016/S0005-7894(05)80270-9CrossRefGoogle Scholar
  143. Wong, S. E., & Woolsey, J. E. (1989). Re-establishing conversational skills in overtly psychotic, chronic schizophrenic patients: Discrete trials training on the psychiatric ward. Behavior Modification, 13, 415–430. 10.1177/01454455890134002CrossRefPubMedPubMedCentralGoogle Scholar
  144. Wong, S. E., Wright, J., Terranova, M. D., Bowen, L., & Zarate, R. (1988). Effects of structured ward activities on appropriate and psychotic behavior of chronic psychiatric patients. Behavioral Residential Treatment, 3, 41–50.Google Scholar

Copyright information

© Stephen E. Wong 2006

Authors and Affiliations

  1. 1.School of Social WorkFlorida International UniversityUSA

Personalised recommendations